Phase 1 Study of L-NMMA in Patients With Liver Cirrhosis

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Phase 1 study of the effects of nitric oxide inhibition with L-NMMA in patients with liver cirrhosis and healthy controls. It is hypothesized that nitric oxide availability is increased in liver cirrhosis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Regional Hospital Holstebro
• Treatments: omega-N-Methylarginine

Criteria

Inclusion Criteria:

Healthy controls

• Age 20 to 60 years

• Both men and women

• Weight below 100 kg

• Normal clinical examination and laboratory screening

• Fertile women only if using contraception

• Informed consent according to the regulations of the local ethics committee

Liver cirrhosis

• Biopsy verified liver cirrhosis or clinical and laboratory signs of liver cirrhosis including hypoalbuminaemia, increased prothrombin time in combination with esophagusvarices or ascites

• P-creatinine < 250 µmol/L

• Age 20-60 years

• Both men and women

• Fertile women only if using contraception

• Body weight below 100 kg

• Informed consent according to the regulations of the local ethics committee

Exclusion Criteria:

Healthy controls

• History or clinical evidence of diseases of the heart and blood vessels, kidneys, liver and pancreas, endocrine organs, lungs, neoplastic disease, myocardial infarction or cerebrovascular insult as evaluated by clinical examination and laboratory screening

• Current medication

• Drugs or alcohol abuse

• Pregnancy

• Previously within one year received more than 0.2 mSV radioactive treatment or diagnostic substances

• Donation of blood less than 1 month before the experiments

Liver cirrhosis

• Apart from liver cirrhosis no history of diseases of the heart and blood vessels, endocrine organs, lungs, myocardial infarction, cerebrovascular insult or neoplastic disease.

• Drugs or alcohol abuse

• Pregnancy

• Previously within one year received more than 0.2 mSV radioactive treatment or diagnostic substances